[
    [
        {
            "time": "",
            "original_text": "暴涨暴跌中：哪些医药股最值得投资？",
            "features": {
                "keywords": [
                    "医药股",
                    "投资"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "暴涨暴跌中：哪些医药股最值得投资？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558）：获批首个国产ALK抑制剂 NSCLC领域实现两翼齐飞",
            "features": {
                "keywords": [
                    "贝达药业",
                    "ALK抑制剂",
                    "NSCLC",
                    "国产"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业（300558）：获批首个国产ALK抑制剂 NSCLC领域实现两翼齐飞",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "中环股份签单超60亿元合同 这些科技股或表现抢眼",
            "features": {
                "keywords": [
                    "中环股份",
                    "合同",
                    "科技股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中环股份签单超60亿元合同 这些科技股或表现抢眼",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【国金晨报】贝达药业：恩莎替尼即将上市，公司业绩新增驱动；南微医学：股权激励方案发布，彰显未来发展信心",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩莎替尼",
                    "南微医学",
                    "股权激励"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国金晨报】贝达药业：恩莎替尼即将上市，公司业绩新增驱动；南微医学：股权激励方案发布，彰显未来发展信心",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558）：恩莎替尼即将上市 公司业绩新增驱动",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩莎替尼",
                    "业绩驱动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业（300558）：恩莎替尼即将上市 公司业绩新增驱动",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]